Shanghai, China Sinopharm Capital is the famous VC, which was founded in 2012. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 51 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.
For fund there is a match between the location of its establishment and the land of its numerous investments - China. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Dingdang Kuaiyao, HealthCare Biotech. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. The fund has no exact preference in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Sinopharm Capital, startups are often financed by ZhenFund, Sequoia Capital China, PrairieGold Venture Partners. The meaningful sponsors for the fund in investment in the same round are TF Capital, Lilly Asia Ventures, YuanMing Capital. In the next rounds fund is usually obtained by Lilly Asia Ventures, TF Capital, Qiming Venture Partners.
Related Funds
| Fund Name | Location |
| Arc Capital Development | Colorado, Denver, United States |
| BMNT | California, Palo Alto, United States |
| Cloud Power Capital | Austin, Texas, United States |
| Corriente Advisors | Fort Worth, Texas, United States |
| Da Vinci Capital | Castel, Guernsey, Guernsey |
| Hegemon Group International | - |
| HSBC Bank Oman | - |
| Landmark Partners | Connecticut, Simsbury, United States |
| Latona Associates | - |
| North Coast Technology Investors | Ann Arbor, Michigan, United States |
| Oisix | Japan, Shinagawa |
| POSCO Venture Partners | Seoul, Seoul-t'ukpyolsi, South Korea |
| SAFA | - |
| Sanchez Capital Partners | Austin, Texas, United States |
| Soaring Capital | Beijing, Beijing, China |
| The Galleon Group | - |
| The Norinchukin Bank | Chiyoda, Japan |
| Zen Water Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Artivila Therapeutics | $15M | 31 Mar 2022 | Shenzhen, Guangdong, China | ||
CytoNiche | $46M | 03 Mar 2022 | Dongcheng District, Beijing, China | ||
Sumgen Biotech | 07 Dec 2021 | Shangcheng District, Zhejiang, China | |||
Longhui Medical | $15M | 26 Nov 2021 | Shanghai, Shanghai, China | ||
Shanghai Ouyi Biomedical Technology | $13M | 02 Nov 2021 | Shanghai, Shanghai, China | ||
Geneus | 28 Sep 2021 | Chengdu, Sichuan, China | |||
FutureGen | $46M | 12 Mar 2021 | - | ||
Huiyi Huiying | $15M | 16 Nov 2020 | Dongcheng District, Beijing, China | ||
Dingdang Kuaiyao | $154M | 20 Oct 2020 | Dongcheng District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Artivila Therapeutics | $15M | 31 Mar 2022 | Shenzhen, Guangdong, China | ||
CytoNiche | $46M | 03 Mar 2022 | Dongcheng District, Beijing, China | ||
Sumgen Biotech | 07 Dec 2021 | Shangcheng District, Zhejiang, China | |||
Longhui Medical | $15M | 26 Nov 2021 | Shanghai, Shanghai, China | ||
Shanghai Ouyi Biomedical Technology | $13M | 02 Nov 2021 | Shanghai, Shanghai, China | ||
Geneus | 28 Sep 2021 | Chengdu, Sichuan, China | |||
FutureGen | $46M | 12 Mar 2021 | - | ||
Huiyi Huiying | $15M | 16 Nov 2020 | Dongcheng District, Beijing, China | ||
Dingdang Kuaiyao | $154M | 20 Oct 2020 | Dongcheng District, Beijing, China |
